Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement Compared With Surgical Valve Replacement in Intermediate-Risk Patients

doi:10.1016/j.jacc.2023.04.049

Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement Compared With Surgical Valve Replacement in Intermediate-Risk Patients

J Am Coll CardiolPublished 11 Jul 2023Propensity-matched comparison of the PARTNER 2 S3 single-arm study and the PARTNER 2A randomised trial

Primary resultResultHazard ratio 0.87 95% CI 0.74–1.03

Read the original article ↗

Cite

Authors' conclusion

In this propensity-matched analysis of intermediate-risk patients, 5-year rates of death and disabling stroke were similar between S3 TAVR and SAVR.

Study context

Population: Intermediate-risk patients with severe AS783 matched pairs

Comparison: S3 transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR)
Primary endpoint: Composite of:
All-cause death
Disabling stroke
Follow-up: 5 years

Methodological detailspropensity-score matched

Propensity-score matched

Primary result

As reported in the abstract

Hazard ratio

0.87

95% CI 0.74–1.03

P = 0.10

By group

S3 TAVR40.2%

SAVR42.7%

S3 TAVR vs SAVR

HR 0.87 (95% CI 0.74–1.03); P = 0.10

Further findings

SVD-related stage 2 and 3 hemodynamic valve deterioration or bioprosthetic valve failure

No differences between S3 TAVR and SAVR

Safety

Mild or greater paravalvular regurgitation

More common after S3 TAVR

Original publication

Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement Compared With Surgical Valve Replacement in Intermediate-Risk Patients. J Am Coll Cardiol. Published 11 July 2023. doi:10.1016/j.jacc.2023.04.049

Read the original article ↗PubMed

Summarised from the published abstract; every number is checked against it